- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, June 10, 2022
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
The CER Daily Newsfeed, a newsletter from the National Pharmaceutical Council (NPC), cited a story on AJMC.com, the website of The American Journal of Managed Care® (AJMC®), about the Federal Trade Commission opening up an investigation into the business practices of the 6 largest pharmacy benefit managers. The story, "In Reversal, FTC Launches Inquiry Into PBM Industry," included interviews with the CEOs of the NPC as well as the Pontchartrain Cancer Center.
A piece by AJMC®'s sister site, Pharmacy Times®, cited a supplemental study published in AJMC®. The study, “Health Outcomes From an Innovative Enhanced Medication Therapy Management Model,” found that medication safety reviews were effective at improving annual health care costs, hospitalizations, emergency department visits, and mortality in Medicare beneficiaries targeted according to MedWise Risk Score.
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Gestational Diabetes Is a Key Population Health Opportunity
December 7th 2023Diagnosing and treating gestational diabetes can have long-term positive effects on the health of the mother and the baby, warranting a distinct focus on the condition, according to an Institute for Value-Based Medicine® event held in Cleveland, Ohio.
Read More
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
